전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,092 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Assistance
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Moxetumomab Pasudotox-tdfk (Moxetumomab Pasudotox-tdfk)

Hairy Cell Leukemia · Hairy Cell Leukemia

#HairyCellLeukemia#Antibody#Phase1#monoclonal-antibody#National
Trials 1Status Recruiting
AntibodyLimited DatastaleMayo ClinicPhase 2

Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine (Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine)

Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinosarcoma · Fallopian Tube Carcinosarcoma

#FallopianTubeCarcinosarcoma#Antibody#Phase2#monoclonal-antibody#PrimaryPeritonealCarcinosarcoma+1
Trials 1Status Recruiting
CGTLimited DatastaleKite, A Gilead CompanyPhase 2

Murine autologous anti-CD19 chimeric antigen receptor T cells (Murine autologous anti-CD19 chimeric antigen receptor T cells)

Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

nivolumab (Opdivo, NAI + Nivolumab + Ipilimumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, NAI + Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

NG2 and DLL3 CAR-T cells (NG2 and DLL3 CAR-T cells)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued

43 / 55 pages

← PreviousNext →